A detailed history of Center Book Partners LP transactions in Argenx Se stock. As of the latest transaction made, Center Book Partners LP holds 6,309 shares of ARGX stock, worth $3.94 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
6,309
Previous 25,919 75.66%
Holding current value
$3.94 Million
Previous $11.1 Million 69.31%
% of portfolio
0.22%
Previous 0.74%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $8.52 Million - $10.8 Million
-19,610 Reduced 75.66%
6,309 $3.42 Million
Q2 2024

Aug 12, 2024

BUY
$356.01 - $451.55 $9.23 Million - $11.7 Million
25,919 New
25,919 $11.1 Million
Q4 2022

Feb 13, 2023

BUY
$342.17 - $402.31 $543,365 - $638,868
1,588 New
1,588 $601,000
Q1 2022

May 16, 2022

SELL
$254.45 - $351.06 $201,524 - $278,039
-792 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$272.01 - $353.03 $215,431 - $279,599
792 New
792 $277,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Center Book Partners LP Portfolio

Follow Center Book Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Center Book Partners LP with notifications on news.